重症肌无力自1879年由Erb氏首次报告以来已将近百年,但本病的治疗却长期停留在使用新斯的明一类抗胆硷酯酶剂上,本剂虽可使症状改善,但疗效短暂,需长期服用,而长期用药又可产生抗药性,最后可造成把剂量再加大也无效的结局。近数十年来由于免疫学的进展,越来越多的证据证明重症肌无力系白体免疫性疾病,这给本病的治疗开辟了一条新路,各国纷纷使用了ACTH或类固醇来治疗本病。早在1935年Simon氏就已证实ACTH在重症肌无力中的治疗价值。1952年Schlezinger氏报告用类固醇治疗的26例有20例获良好效果。但由于在用药过程中恶化现象的出现,激素疗法曾一度被冷落下来,直至1960年Freydberg氏再次肯定了ACTH疗法。此后有人认为用类固醇也能得到与ACTH大致相同的结果,不管用那种药物,大剂量以后的症状改善率高达90％左 Myasthenia gravis has been around for nearly a century since Erb’s first report in 1879. However, the treatment of this disease has long been on the use of neostigmine-based anti-cholinesterase agents. Although this agent can improve the symptoms, the efficacy Short-term, long-term use, long-term medication can produce resistance, and finally can cause the dose to increase and also invalid outcome. In recent decades due to the progress of immunology, more and more evidence that myasthenia gravis is an autoimmune disease, which has opened up a new path for the treatment of this disease, countries have used ACTH or steroids to treat the disease . As early as 1935, Simon has demonstrated the value of ACTH in the treatment of myasthenia gravis. In 1952, Schlezinger reported good results in 20 of 26 patients treated with steroids. However, hormonal therapy was once subsided due to the worsening of medication, until Freydberg’s reaffirmation of ACTH therapy in 1960. Since then, some people think that with steroids can get the same results with ACTH, regardless of the use of drugs, high dose of symptoms after the improvement rate of up to 90%